Physician profile
Nancy A Becker
NPI 1679582654
$5,578.93
in general payments reported to CMS, 2019-2025
34 companies · $1,849 in 2025
The $1,849 reported for 2025 was more than what 88% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $169 · 2021: $686 · 2022: $467 · 2023: $1,104 · 2024: $1,054 · 2025: $1,849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,996 · Education: $10.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,996.00 |
| Education | $10.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,359.41 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $618.34 | 2021-2025 | Nucala, Trelegy Ellipta |
| Aerin Medical INC. | $514.53 | 2019-2023 | |
| Revance Therapeutics, INC. | $472.92 | 2024-2025 | Daxxify |
| Merz North America, INC. | $347.74 | 2019-2024 | Xeomin |
| Genzyme Corporation | $318.97 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $292.74 | 2019-2025 | Dupixent |
| Kaleo, INC. | $286.83 | 2021-2024 | Auvi-Q |
| Phathom Pharmaceuticals, INC. | $224.36 | 2024-2025 | Voquezna |
| Abbvie INC. | $204.02 | 2022-2025 | |
| Optinose US, INC. | $108.56 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $96.45 | 2019-2025 | |
| Galderma Laboratories, L.P. | $72.69 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $64.32 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $64.32 | 2025 | Neffy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $53.45 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.02 | 2022-2023 | Cuvitru |
| Mimedx Group, INC. | $41.02 | 2024-2025 | |
| Smith+Nephew, INC. | $40.33 | 2021-2025 | Grafix Pl |
| 3b Medical, INC. | $35.91 | 2023-2025 | Luna |
| Alk-Abello, INC | $34.47 | 2023-2024 | Ragwitek, Odactra, Grastek |
| Paratek Pharmaceuticals, INC. | $32.50 | 2025 | Xhance |
| Fisher & Paykel Healthcare INC | $29.00 | 2025 | Fisher & Paykel Healthcare |
| Greer Laboratories, INC. | $28.62 | 2022 | |
| Amgen INC. | $24.71 | 2025 | Tezspire |
| Inspire Medical Systems, INC. | $24.54 | 2025 | Inspire |
| Genentech USA, INC. | $23.03 | 2025 | Xolair |
| Ascensia Diabetes Care US INC. | $21.18 | 2023 | |
| Medtronic, INC. | $17.21 | 2023 | Nuvent |
| Organogenesis INC. | $16.98 | 2025 | Affinity |
| Acell, INC. | $16.16 | 2020 | |
| Intersect Ent, INC. | $15.27 | 2020 | |
| Uswm, LLC | $15.00 | 2021 | |
| Xoran Technologies LLC | $14.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.